Clinical, laboratory and ultrasonographic findings at baseline predict long-term outcome of polymyalgia rheumatica: a multicentric retrospective study : Polymyalgia rheumatica predicted by ultrasonographic findings polymyalgia rheumatica outcome predicted early by ultrasound.
Arthritis
Giant cell arteritis
Polymyalgia rheumatica
Ultrasonography
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
28
03
2023
accepted:
10
07
2023
medline:
2
10
2023
pubmed:
27
7
2023
entrez:
27
7
2023
Statut:
ppublish
Résumé
To assess the rate of PMR who, during the follow-up, undergo a diagnostic shift as well as to assess which clinical, laboratory and US findings are associated to a diagnostic shift and predict the long-term evolution of PMR. All PMR followed-up for at least 12 months were included. According to the US procedures performed at diagnosis, patients were subdivided into four subgroups. Clinical data from follow-up visits at 12, 24, 48 and 60 months, including a diagnostic shift, the number of relapses and immunosuppressive and steroid treatment, were recorded. A total of 201 patients were included. During the follow-up, up to 60% had a change in diagnosis. Bilateral LHBT was associated with persistence in PMR diagnosis, whereas GH synovitis and RF positivity to a diagnostic shift. Patients undergoing diagnostic shift had a higher frequency of GH synovitis, shoulder PD, higher CRP, WBC, PLT and Hb and longer time to achieve remission, while those maintaining diagnosis had bilateral exudative LHBT and SA-SD bursitis, higher ESR, lower Hb and shorter time to remission. Cluster analysis identified a subgroup of older patients, with lower CRP, WBC, PLT and Hb, lower PD signal or peripheral synovitis who had a higher persistence in PMR diagnosis, suffered from more flares and took more GCs. Most PMR have their diagnosis changed during follow-up. The early use of the US is associated with a lower dosage of GCs. Patients with a definite subset of clinical, laboratory and US findings seem to be more prone to maintain the diagnosis of PMR.
Identifiants
pubmed: 37498353
doi: 10.1007/s11739-023-03373-x
pii: 10.1007/s11739-023-03373-x
pmc: PMC10543828
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1929-1939Subventions
Organisme : AbbVie
ID : 0068880
Informations de copyright
© 2023. The Author(s).
Références
Ann Rheum Dis. 1979 Oct;38(5):434-9
pubmed: 518143
Ann Rheum Dis. 2018 Dec;77(12):1730-1735
pubmed: 30076154
Rheumatology (Oxford). 2020 Oct 1;59(10):2764-2773
pubmed: 32031663
Semin Arthritis Rheum. 2019 Feb;48(4):720-727
pubmed: 29903537
Arthritis Rheum. 2006 Aug 15;55(4):518-20
pubmed: 16874793
Joint Bone Spine. 2022 May;89(3):105325
pubmed: 34915108
Arthritis Rheum. 1997 Oct;40(10):1873-8
pubmed: 9336424
J Rheumatol. 2002 Apr;29(4):748-56
pubmed: 11950017
J Rheumatol. 2017 Feb;44(2):241-247
pubmed: 27980012
J Clin Endocrinol Metab. 1998 Jun;83(6):2012-7
pubmed: 9626133
Clin Exp Rheumatol. 2021 Jan-Feb;39(1):84-90
pubmed: 32242812
J Rheumatol. 2000 Sep;27(9):2179-84
pubmed: 10990231
Ann Rheum Dis. 2018 Dec;77(12):1750-1756
pubmed: 30297332
Semin Arthritis Rheum. 2022 Aug;55:152017
pubmed: 35537222
Front Med (Lausanne). 2022 Nov 16;9:1042620
pubmed: 36465900
J Rheumatol. 2005 Jun;32(6):1043-6
pubmed: 15940765
Joint Bone Spine. 2022 Oct;89(5):105378
pubmed: 35288264
Rheumatol Adv Pract. 2022 May 11;6(2):rkac034
pubmed: 35591903
Arthritis Rheum. 2012 Apr;64(4):943-54
pubmed: 22389040
Ann Rheum Dis. 2001 Nov;60(11):1021-4
pubmed: 11602472
Ann Intern Med. 2017 May 2;166(9):ITC65-ITC80
pubmed: 28460395
Rheumatology (Oxford). 2022 Mar 2;61(3):1185-1194
pubmed: 34164671
Joint Bone Spine. 2023 Jul;90(4):105529
pubmed: 36690063
Rheumatology (Oxford). 2009 Dec;48(12):1566-9
pubmed: 19808693
Scand J Rheumatol. 2011 Jan;40(1):57-63
pubmed: 20653466
Rheumatology (Oxford). 2023 Aug 1;62(8):2797-2805
pubmed: 36637182
Clin Rheumatol. 2022 Jan;41(1):19-31
pubmed: 34415462
Rheumatology (Oxford). 2017 Apr 1;56(4):506-515
pubmed: 27481272
Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii22-ii31
pubmed: 29982780
Rheumatology (Oxford). 2021 Mar 2;60(3):1016-1033
pubmed: 33200216
Ann Rheum Dis. 2015 Oct;74(10):1799-807
pubmed: 26359488
Reumatismo. 2020 Apr 10;72(1):1-15
pubmed: 32292016
Rheumatology (Oxford). 2020 Aug 1;59(8):1906-1915
pubmed: 31742642
Ann N Y Acad Sci. 2002 Jun;966:91-6
pubmed: 12114263
Rheumatol Int. 2020 Jul;40(7):1101-1109
pubmed: 32062696
Rheumatology (Oxford). 2023 May 02;:
pubmed: 37129541
Biomed Res Int. 2017;2017:4272560
pubmed: 28293635
Rheumatology (Oxford). 2010 Jan;49(1):186-90
pubmed: 19910443
Reumatologia. 2020;58(2):76-80
pubmed: 32476679
Rheumatology (Oxford). 2000 Jun;39(6):624-31
pubmed: 10888707
Arthritis Rheum. 2007 Jun 15;57(5):803-9
pubmed: 17530680
Rheumatol Int. 2000;19(5):185-9
pubmed: 10984136
RMD Open. 2015 Aug 13;1(1):e000100
pubmed: 26535139
RMD Open. 2017 Jul 11;3(1):e000428
pubmed: 28948983
Clin Exp Rheumatol. 2020 Nov-Dec;38(6):1170-1175
pubmed: 32141428